Cytokines, sepsis and immunomodulation
- PMID: 8472134
- DOI: 10.1002/bjs.1800800308
Cytokines, sepsis and immunomodulation
Abstract
Tissue injury and infection produce significant alterations in host metabolic and immune homeostasis. It is increasingly clear that many of these changes result from a complex cascade of mononuclear phagocyte-derived endogenous mediators. Among the more important is a group of host proteins called cytokines, which play an integral role in mediating the host response to tissue injury and infection. Of these proteins, tumour necrosis factor (TNF) and interleukin (IL) types 1 and 6 have received much attention for their pathophysiological roles in infection and trauma. Evidence is reviewed for the involvement of these cytokines in the characteristic alterations in the metabolic and immune responses to such injury. These endogenous mediators initiate an integrated fuel substrate and hormonal adjustment to trauma and sepsis, and help to provide optimal metabolic homeostasis for systemic host defences. Widespread tissue injury, especially when associated with fulminant sepsis, may, however, precipitate massive release of TNF, IL-1 and IL-6, triggering a series of reactions involving multiple organs, and culminating in the 'sepsis syndrome'. New therapies designed to downregulate this aberrant response, either by neutralizing endotoxin directly or by blocking the release or actions of these cytokines, are reviewed. Although these treatments hold much promise for the future management of severely traumatized and infected patients, careful evaluation of both the benefits and complications of therapy is needed before widespread clinical use can be recommended.
Similar articles
-
Tumour necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature.Neth J Med. 1991 Aug;39(1-2):45-62. Neth J Med. 1991. PMID: 1961351 Review.
-
[Similarity and synergy of trauma and sepsis: role of tumor necrosis factor-alpha and interleukin-6].Acta Anaesthesiol Sin. 1996 Sep;34(3):141-9. Acta Anaesthesiol Sin. 1996. PMID: 9084538 Review. Chinese.
-
Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.J Exp Med. 1989 Nov 1;170(5):1627-33. doi: 10.1084/jem.170.5.1627. J Exp Med. 1989. PMID: 2809510 Free PMC article.
-
Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade.Crit Care Med. 1993 May;21(5):780-9. Crit Care Med. 1993. PMID: 8482101 Review.
-
[Physiopathology of severe sepsis].Presse Med. 2004 Feb 28;33(4):256-61; discussion 269. doi: 10.1016/s0755-4982(04)98551-x. Presse Med. 2004. PMID: 15029017 Review. French.
Cited by
-
Metabolism, Metabolomics, and Nutritional Support of Patients with Sepsis.Clin Chest Med. 2016 Jun;37(2):321-31. doi: 10.1016/j.ccm.2016.01.011. Epub 2016 Mar 12. Clin Chest Med. 2016. PMID: 27229648 Free PMC article. Review.
-
Pre-treatment and continuous administration of simvastatin during sepsis improve metabolic parameters and prevent CNS injuries in survivor rats.Mol Cell Biochem. 2022 Nov;477(11):2657-2667. doi: 10.1007/s11010-022-04463-8. Epub 2022 May 23. Mol Cell Biochem. 2022. PMID: 35604517
-
In Vitro and In Vivo Anti-Inflammatory Effects of Polyphyllin VII through Downregulating MAPK and NF-κB Pathways.Molecules. 2019 Mar 1;24(5):875. doi: 10.3390/molecules24050875. Molecules. 2019. PMID: 30832224 Free PMC article.
-
Detection of neopterin, interleukin-6 and acute-phase proteins as parameters of potential monocyte activation in preoperative patients.Infection. 1995 Sep-Oct;23(5):263-6. doi: 10.1007/BF01716282. Infection. 1995. PMID: 8557382
-
Sepsis and septic shock. II. Treatment.Support Care Cancer. 1995 Mar;3(2):111-9. doi: 10.1007/BF00365850. Support Care Cancer. 1995. PMID: 7773578 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources